<DOC>
	<DOCNO>NCT01260844</DOCNO>
	<brief_summary>Phase 1 , drug-drug interaction study evaluate effect Briakinumab hte pharmacokinetics single dos CYP substrate subject moderate severe psoriasis .</brief_summary>
	<brief_title>Open Label , Single Dose , Non-randomized Study Assess Drug Drug Interaction Briakinumab CYP Substrates .</brief_title>
	<detailed_description>The study involve 3 day confinement begin trial 4 day end trial . The trial duration 17 day 6 visit include confinement period . The trial conduct moderate severe plaque psoriasis subject . Serial blood sample take dos CYP substrate administer blood sample collect briakinumab PK briakinumab ADA .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female age 18 55 year , inclusive . 2 . Clinical diagnosis plaque psoriasis least 6 month determine subject 's interview his/her medical history confirmation diagnosis physical examination investigator . 3 . Moderate severe plaque psoriasis define ≥ 10 % Body Surface Area ( BSA ) involvement Screening visit Day 2 visit . 4 . PGA least moderate ( defined PGA ≥3 ) disease Screening visit Day 2 visit . 5 . Subject judge good general health determine principal investigator base upon result medical history , laboratory profile , physical examination , chest xray , 12lead electrocardiogram ( ECG ) perform Screening . 6 . Females must negative result pregnancy test study . 7 . Body Mass Index ( BMI ) 18 29 , inclusive . Exclusion Criteria 1 . History either Type 1 2 diabetes 2 . History significant sensitivity drug 3 . History drug alcohol abuse within 6 month prior screen 4 . Receipt investigational product within 1 month prior day 2 , current participation clinical study receive study drug device 5 . Use known CYP inhibitor ( e.g. , ketoconazole , clotrimazole ) inducer ( e.g. , dexamethasone , phenytoin , rifampin , carbamazepine ) within 1 month prior Day 2 6 . Use known CYP substrate , ( include hormonal contraception ) , within 1 month prior Study Day2 . See Appendix E List Cytochrome P450 ( CYP ) Medications Treatment Hypertension Dyslipidemia 7 . Receipt vaccine within 3 month prior study drug administration 8 . Subject receive vaccination Bacille CalmetteGuérin ( BCG ) 9 . Previous exposure systemic antiIL12/23 therapy , include briakinumab ( ABT874 ) ustekinumab . 10 . Can discontinue systemic therapy treatment psoriasis , systemic therapy know improve psoriasis , study : Nonbiologic systemic ( investigational market ) therapy must discontinue least 1 month prior Day2 Biologic ( investigational market ) therapy must discontinue least 12 week prior Day2 11 . Subjects must use topical therapy treatment psoriasis corticosteroid , vitamin D analog , retinoids study . Subjects allow use : Shampoos contain corticosteroid ; Bland ( without beta alpha hydroxy acid ) emollient ; Low potency ( Class VI Class VII ) topical corticosteroid palm , sol , face , inframammary area , groin . See Appendix F Listing Examples Class VI VII Topical Corticosteroids 12 . Can avoid PUVA phototherapy study . 13 . Subject take require oral , injectable inhaled corticosteroid study . 14 . Use herbal dietary supplement , St. John 's Wort , within 1 month prior Day 2 10 half life whichever longer . 15 . Use caffeine and/or theobromine ( coffee , chocolate , tea , cola drink , mountain dew etc . ) within three day prior Day2 Day 12 . 16 . Consumption orange , grapefruit orange grapefruit product ( juice ) , broccoli , brussels sprout , charcoal grill meat within three day prior Day2 Day 12 17 . Consumption alcohol within 48 hour prior Day2 Day 12 . 18 . Use tobacco nicotinecontaining product within 6month period precede Day2 . 19 . Positive screen drug abuse , alcohol cotinine 20 . Female subject pregnant breastfeeding consider become pregnant study 60 day receive single dose study drug 21 . Positive test result hepatitis A virus immunoglobulin M ( HAVIgM ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCV Ab ) HIV antibody ( HIV Ab ) . Negative HIV status confirm Screening , result maintain communicated subject confidentially study site . 22 . History gastric surgery , cholecystectomy , vagotomy , bowel resection surgical procedure might interfere gastrointestinal motility , pH absorption 23 . Donation loss 550 mL blood volume ( include plasmapheresis ) receipt transfusion blood product within 8 week Day2 . 24 . Diagnosis erythrodermic psoriasis , generalize localized pustular psoriasis , medicationinduced medication exacerbate psoriasis , new onset guttate psoriasis . 25 . Poorly control medical condition , document history recurrent infection , unstable ischemic heart disease , congestive heart failure , recent cerebrovascular accident condition , unstable psychiatric condition , opinion investigator and/or Abbott 's Medical Monitor , would put subject risk participation study 26 . Subject infection risk factor severe infection , example : Active tuberculous disease ; Evidence latent tuberculosis ( TB ) infection demonstrate positive result Purified Protein Derivative ( PPD ) skin test Subject take TB prophylaxis medication Any significant infection require hospitalization intravenous ( IV ) antibiotic month prior Day 2 ; Infection require treatment antibiotic month prior Day 2 27 . History atherosclerotic cardiovascular disease manifest follow : 28 . History malignancy successfully treat basal cell carcinoma , nonmetastatic cutaneous squamous cell carcinoma cervical carcinoma situ 29 . Exacerbation asthma require hospitalization 10 year prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>